Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05053854
Other study ID # PMC67199
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date December 8, 2021
Est. completion date December 31, 2025

Study information

Verified date October 2023
Source Peter MacCallum Cancer Centre, Australia
Contact Grace Kong
Phone 85595000
Email NMResearch@petermac.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase 1 dose-escalation study is designed to evaluate the safety and tolerability of talazoparib in combination with 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy (PRRT) in patients with metastatic pancreatic or midgut neuroendocrine tumour (NET).


Description:

This phase 1, single arm, single centre study is designed to evaluate the safety and tolerability of talazoparib in combination with 177Lu-DOTA-Octreotate in patients with metastatic NET. Patients will receive 1 cycle of 177Lu-DOTA-Octreotate alone followed by 3 cycles of 177Lu-DOTA-Octreotate combined with 5 days of talazoparib.


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patient must be > or equal to18 years of age and must have provided written informed consent. 2. Eastern Cooperative Oncology Group (ECOG) performance status of = 2 3. Histologically confirmed Grade 2 NET, Ki-67 of 3-20%, from pancreatic or intestinal origin. 4. Patient clinically suitable for PRRT 5. Tumor SSR uptake on GaTate PET/CT higher than liver activity, = modified Krenning 3 score 6. No discordant FDG-avid disease on FDG PET/CT 7. No evidence of significant uncorrected carcinoid heart disease 8. Patients must be willing and able to comply with the protocol for the duration of the study including undergoing treatment, scheduled assessments 9. Patients must have adequate bone marrow, hepatic and renal function defined as: - Haemoglobin =100 g/L - Absolute neutrophil count =1.5x109/L - Platelets =150 x109/L - Total bilirubin =1.5 x upper limit of normal (ULN) - Aspartate transaminase (AST) (SGOT) and alanine transaminase (ALT) (SGPT) =2.5 x ULN if there is no evidence of liver metastasis or =5 x ULN in the presence of liver metastases. - Albumin = 30 g/L - Adequate renal function: eGFR = 60 ml/min Exclusion Criteria: 1. Surgery or radiotherapy within <3 weeks of registration. Patients must have recovered from any effects of any major surgery. 2. Any prior exposure to peptide receptor radionuclide therapy (177Lu, 111In or 90Y labelled), PARPi, immunotherapy 3. Uncontrolled intercurrent illness that is likely to impede participation and /or compliance 4. Other malignancies unless curatively treated with no evidence of disease within previous 3-years other than adequately treated non-melanoma skin cancer or melanoma in situ. 5. Previous or current history of myelodysplastic syndrome/acute myeloid leukemia 6. Patients unable to swallow orally administered medications or with gastrointestinal disorders likely to interfere with the absorption of the study medication. 7. Use of strong P-gp inhibitors (eg, dronedarone, quinidine, ranolazine, verapamil, ketoconazole, itraconazole), P-gp inducers (eg, rifampin, tipranavir/ritonavir), or BCRP inhibitors (eg, elacridar [GF120918]) should be avoided. 8. Participation in another clinical study with an investigational product or another systemic therapy administered in the last 3 weeks (except short acting SSA).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Talazoparib
During dose escalation, doses of talazoparib that can be administered are 0.1mg, 0.25mg, 0.5mg or 1mg oral daily. Talazoparib will be given on days 2-6 of each cycle of 177Lu-DOTA-Octreotate for cycles 2-4, every 8 weeks

Locations

Country Name City State
Australia Peter MacCallum Cancer Centre Melbourne Victoria

Sponsors (1)

Lead Sponsor Collaborator
Peter MacCallum Cancer Centre, Australia

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose Talazoparib with 177Lu-DOTA-Octreotate Maximum tolerated dose of Talazoparib when given in combination with 177Lu-DOTA-Octreotate Through study completion, up to 18 months following first administration of PRRT.
Primary Dose limiting toxicity talazoparib The toxicity (haematologic or non-haematologic) that prevents further administration of the trial talazoparib treatment at that dose level. Each cohort of 3 patients be assessed for DLTs in the first 6 weeks (cycle 2) of treatment and a dose for the next cohort will be determined (each cycle is 8 weeks)
Secondary Adverse Events and Serious Adverse Events measured using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 Safety of the combination will be measured by AEs and SAEs Through Study completion, up to 18 months after the last patient commences treatment.
Secondary Radiographic progression free survival The time from treatment initiation to the first date of progression on imaging or death due to any cause. Imaging progression will be assessed by RECIST 1.1. Patients who commence new systemic therapy before evidence of disease progression on conventional imaging will be considered to have progressed. Through study completion, up to 18 months following first administration of PRRT.
Secondary Overall Survival The time from treatment initiation to the date of death due to any cause. For patients alive, the time will be censored at the last time the patients was known to be alive. Through study completion, up to 18 months following first administration of PRRT.
Secondary Treatment discontinuation due to toxicity The number of patients who discontinue treatment at any time due to treatment related toxicity will be reported and will be also categorised by dose level. Through study completion, up to 18 months following first administration of PRRT.
Secondary Rate of Treatment discontinuation due to toxicity The percentage of patients who discontinue treatment due to treatment related toxicity will be reported and will be also categorised by dose level Through study completion, up to 18 months following first administration of PRRT.
See also
  Status Clinical Trial Phase
Completed NCT01218555 - Study of Everolimus (RAD001) in Combination With Lenalidomide Phase 1
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Withdrawn NCT04614766 - A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors Phase 1/Phase 2
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Completed NCT03273712 - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) Phase 2
Recruiting NCT05636618 - Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors Phase 1/Phase 2
Terminated NCT03986593 - Cryoablation of Bone Metastases From Endocrine Tumors N/A
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Completed NCT02815969 - The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors
Completed NCT02441062 - Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors Phase 2
Active, not recruiting NCT02174549 - Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer Phase 1/Phase 2
Completed NCT02134639 - PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation N/A
Completed NCT02132468 - A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers Phase 2
Recruiting NCT01201096 - Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE) N/A
Terminated NCT01163526 - Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies N/A
Completed NCT01099228 - Combination Targeted Radiotherapy in Neuroendocrine Tumors N/A
Completed NCT00171873 - Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut Phase 3
Active, not recruiting NCT05077384 - Open-label Study of Surufatinib in Japanese Patients Phase 1/Phase 2
Active, not recruiting NCT04544098 - Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver Early Phase 1
Active, not recruiting NCT02736500 - Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors Phase 1/Phase 2